Published in Hepatitis Weekly, August 24th, 2009
"The aim of this study was to investigate the extent to which such RIBA-indeterminate donors had previously been exposed to HCV. T-cell responses to HCV recombinant proteins (core, NS3, and NS3 helicase) were analyzed using an interferon-gamma (IFN-gamma) enzyme-linked immunospot (ELISpot) assay and quantification of cytokines in culture supernatants in 27 RIBA-indeterminate donors, 60 RIBA-confirmed donors...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2009-08-24)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.